The battle against cancer is one that has engaged the global medical community for decades, and with the emergence of Chimeric Antigen Receptor (CAR) T-cell therapy, we stand on the precipice of a significant revolution in the way cancer is treated. This immunotherapy transforms a patient's
Introduction Retro Biosciences, a pioneering biotech company, has embarked on an ambitious journey to extend human lifespan by a decade through innovative approaches to combat cellular aging. Its strategic partnership with Multiply Labs, a firm celebrated for advanced automation and robotic
The relentless progress of medical technology regularly unlocks new arenas in the battle against disease, with one of the most notable being the potent capabilities of Natural Killer (NK) cell therapies. As critical members of the immune system, NK cells have become the cornerstone of an innovative
Multiple myeloma (MM), a cancer that attacks the plasma cells in bone marrow, often evades cure, pushing scientists to constantly search for breakthrough therapies. Chimeric Antigen Receptor (CAR) T cell therapy represents one of the most innovative and promising strategies against relapsed MM. Its
The biotech startup Limula, founded in 2020, has announced the triumphant completion of a seed funding round, obtaining a significant $6.8 million. This investment is a clear indication of the potential seen in Limula's groundbreaking approach to cell and gene therapy. With such therapies
Engineered T-cell receptor (TCR) therapies hold a promising future in the realm of oncology, particularly for solid tumors—long considered a formidable adversary due to their complex microenvironment. In a strategic move, AmplifyBio and Xcell Biosciences have joined forces with a shared vision of b
